Secondary Logo

P-G5 Differential immune response to HCV peptides as cancer-progression biomarkers of HCV-infections

Tornesello, AnnaLucia*; Reimer, Ulf; Holenya, Pavlo; Knaute, Tobias; Tornesello, MariaLina*; Maria Buonaguro, Franco*

JAIDS Journal of Acquired Immune Deficiency Syndromes: April 2018 - Volume 77 - Issue - p 63
doi: 10.1097/01.qai.0000532503.32406.e2
Abstracts: PDF Only

HCV infections are the main cause of chronic liver disease and in part of lymphoproliferative disorders. Most HCV infections (>90%) determine chronic hepatitis, 30% of which progress to liver cirrhosis and 3% annually to Hepatocellular Carcinoma (HCC). The progression rate is mainly articulated in low (>40 years) and high (<10 years) speed progressors, with the latter being associated to male gender, <40 years of age, >150mL daily alcohol consumption. Current progression markers are mainly based on biochemical evaluation of liver damage (elevation of alanine and aspartate transaminases) and inflammation (elevation of alpha-fetoprotein). Such markers are not specific and elevated also for other infections (ie, HBV and HCMV) or metabolic disorders (ie, steatosis). Specific HCV-related markers would be relevant to identify HCV co-factors and to select high priority people for direct anti-viral treatment.

To identify HCC progression markers, samples from HCV+ patients at different infection stage have been analyzed on the HCV-peptide platform newly developed by JPT Peptide Technologies GmbH (Germany). It covers the complete HCV-protein arrays with >3000 overlapping 15-amino-acid-long peptides from all structural and non structural HCV proteins. The currently available data (from 7 HCV+ asymptomatic, 5 HCV+ with cryoglobulinemia, 9 HCV cirrhosis/HCC and 5 HCV− patients) demonstrates that in asymptomatic patients the level of anti-HCV is in general very low (including anti-capsid/core proteins), while high levels of immunoresponse anti-non-structural proteins is present in patients with liver cancer. Confirmation of such data would support the anti-non structural response as biomarker of cancer progression in HCV+ patients.

*Istituto Nazionale Tumori—IRCCS Fondazione Pascale, Naples, Italy; and

JPT Peptide Technologies GmbH - Volmerstrasse 5 - 12489 Berlin, Germany

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.